TY - JOUR T1 - Bead-assisted SARS-CoV-2 multi-antigen serological test allows effective identification of patients JF - medRxiv DO - 10.1101/2021.04.08.21254348 SP - 2021.04.08.21254348 AU - Yaiza Cáceres-Martell AU - Daniel Fernández-Soto AU - Carmen Campos-Silva AU - Eva M. García-Cuesta AU - Jose M Casasnovas AU - David Navas-Herrera AU - Alexandra Beneítez-Martínez AU - Pedro Martínez-Fleta AU - Arantzazu Alfranca AU - Francisco Sánchez-Madrid AU - Gabriela Escudero López AU - Carlos Vilches AU - Ricardo Jara-Acevedo AU - Hugh T. Reyburn AU - José M. Rodríguez Frade AU - Mar Valés-Gómez Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/04/10/2021.04.08.21254348.abstract N2 - Many new aspects of COVID-19 disease, including different clinical manifestations, have been identified during the pandemic. The wide array of symptoms and variation in disease severity after SARS-CoV-2 infection might be related to heterogeneity in the immune responses of different patients. Here we describe a new method for a simple multi-antigen serological test that generates a full picture of seroconversion in a single reaction. The assay is based on the detection by flow cytometry of multiple immunoglobulin classes (isotypes) specific for four SARS-CoV-2 antigens: the Spike glycoprotein (one of the highly immunogenic proteins), its RBD fragment (the major target for neutralising antibodies), the nucleocapsid protein and the main cysteine-like protease. Until now, most diagnostic serological tests measured antibodies to only one antigen and some patients seemed to not make any antibody response. Our data reveal that while most patients respond against all the viral antigens tested, others show a marked bias to make antibodies against either proteins exposed on the viral particle or those released after cellular infection. Combining all the four antigens and using machine learning techniques, it was possible to clearly discriminate between patients and healthy controls with 100% confidence. Further, combination of antigens and different immunoglobulin isotypes in this multi-antigen assay improved the classification of patients with mild and severe disease. Introduction of this method will facilitate massive screenings of patients to evaluate their immune response. It could also support vaccination campaigns both to select non-immune individuals and to distinguish infected patients from vaccine responders.Competing Interest StatementJMRF, JMC, HTR and MVG are inventors on the European patent Assay for the detection of the Cys-like protease (Mpro) of SARSCoV-2 [EP20382495.8]. RJ is CEO of Immunostep, S.L. The rest of the authors declare no potential conflict of interest.Funding StatementThis work was supported by the Spanish National Research Council (CSIC, project numbers 202020E079 and CSIC-COVID19-028) and grants from Madrid Regional Government IMMUNOTHERCAN [S2017/BMD-3733-2 (MVG)]; the Spanish Ministry of Science and Innovation [(MCIU/AEI/FEDER, EU): RTI2018-093569-B-I00 (MVG), SAF2017-82940-R (JMRF), SAF2017-83265-R (HTR); SAF2017-82886-R (FSM)]; Health Institute Carlos III (ISCIII) [RETICS Program RD16/0012/0006; RIER (JMRF); PI19/00549 (AA)]. The study was also funded by La Caixa Banking Foundation (HR17-00016 to FSM) and Fondo Supera COVID (CRUE-Banco de Santander) to FSM.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Research project Immune response dynamics as predictor of COVID-19 disease evolution. Implications for therapeutic decision-making approved by La Princesa Health Research Institute Research Ethics Committee (register # 4070) Biobank Hospital Universitario Puerta de Hierro Majadahonda (HUPHM)/Instituto de Investigacion Sanitaria Puerta de Hierro-Segovia de Arana (IDIPHISA) (PT17/0015/0020 in the Spanish National Biobanks Network) project Development of serological assays for detection of viral antigens (SARS-COV2). The protocol was approved by the Bioethics Committees: CEIm Area de Salud Valladolid Este, Hospital Clinico Universitario de Valladolid, with the number/BIO 2020-98-COVIDAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are available upon request ER -